Presentation Audio and Slides Available Live and Via Webcast
NEW YORK--(BUSINESS WIRE)--
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®,
an FDA approved optical diagnostic device that assists dermatologists in
the diagnosis of melanoma, today announced its CEO, Rose Crane, will
present at the SeeThruEquity
Winter Microcap Investor Conference on February 6, 2014 at 9:30 am
ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan,
Controller; and Diana Garcia Redruello, head of the MelaFind Commercial
Team will be available for one-on-one meetings that day.
Ms. Crane will review the Company’s refocused go-to-market strategy for
MelaFind®, including its sales and marketing efforts
targeting leading medical dermatologists in the U.S. and Europe.
Access to the webcast and presentation will be available live during the
conference at 9:30am EST on February 6, 2014 via the following links:
Live Audio Webcast:MELA
Sciences' Corporate Presentation
MELA Sciences will also be participating at the 10th
Annual Maui Derm Conference at the Grand Wailea Hotel, January 26 –
30, 2014. The conference is designed to increase physicians’ knowledge
of developments in both medical and cosmetic dermatology. MELA will
exhibit four clinical posters at the event as well as host a MelaFind®
workshop on Sunday, January 26. Dr. Monica Scheel, who recently
presented new real-world clinical data at MELA Sciences’ Clinical
Advisory meeting at the Winter Clinical Dermatology Conference – Hawaii®
last week, will host the workshop.
Please follow us:
About MELA Sciences, Inc.www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The flagship
product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible
to near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the relative
disorganization of a lesion's cell structure that provides substantial
additional perspective to aid melanoma diagnosis. MELA is also exploring
new potential uses for its core imaging technology and algorithms.
MELA Sciences, Inc.
Diana Garcia Redruello,
Source: MELA Sciences, Inc.